Vivos Therapeutics Inc Ordinary Shares VVOS
News
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Therapeutics Announces Material Debt Reduction
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
